PARADIGM-4TB II期结果:含新型_agents的四联方案在结核病早期治疗中优于标准HRZE
Two Tuberculosis Regimens Containing Novel Agents Show Promise
PARADIGM-4TB适应性平台II期研究显示,含新型药物ganfeborole或BTZ-043的四联方案比标准HRZE方案更快清除分枝杆菌:时间阳性斜率较HRZE分别提高9.1%和20.5%,优越后验概率分别为0.83和0.99;但Harvard配套社论指出该替代终点主要反映大量细菌清除而非持久存活菌群,临床预后改善尚不确定,建议谨慎推进至III期。
— Phase II platform trial's design could speed development of new combinations for TB
November 19, 2026 • 3 min read
- A phase II study showed that two four-drug regimens that combined new agents with commonly used drugs showed promise in tuberculosis.
- The posterior probability of superiority was 0.83 and 0.99 with the two regimens versus the standard four-drug regimen.
- The study's design outlines a potentially useful approach to prioritizing which regimens should be tested in phase III trials.
Two four-drug regimens that combined new agents with commonly used drugs showed promise in tuberculosis (TB), and should be evaluated further, results from a phase II trial suggested.
The time to positivity slope -- the rate of change from baseline to week 12 in the time to Mycobacterium tuberculosis growth in a positive sputum culture, with a steeper time indicating faster TB clearance -- was 0.129 log10 (days) per week with investigational ganfeborole plus bedaquiline, pretomanid, and moxifloxacin (BPMG) and 0.142 log10 (days) per week with investigational BTZ-043 plus bedaquiline, delamanid, and moxifloxacin (BDMT), as compared with 0.118 log10 (days) per week with standard isoniazid, rifampin, pyrazinamide, and ethambutol (HRZE), for relative differences of 9.1% and 20.5%, respectively.
The posterior probability of superiority was 0.83 and 0.99 with the BPMG and BDMT regimens versus HRZE, reported Nicholas Paton, MD, of National University of Singapore, and colleagues in the New England Journal of Medicine.
At week 48, 80% of those in the BPMG group and 93% of those in the BDMT group had favorable-outcome status compared with 89% of the HRZE group.
"Our findings show the potential of large-scale, early-phase clinical trials for evaluating multiple regimens simultaneously with a design that permits the use of early data on treatment failure or relapse to inform selection of regimens for further evaluation," Paton and colleagues wrote.
The four-drug combinations will move on to testing in the phase II trial's second stage.
In an accompanying editorial, Eric Rubin, MD, PhD, of the Harvard T.H. Chan School of Public Health in Boston, cautioned that the number of new TB agents in the development pipeline "creates a combinational nightmare."
This study outlines "a potentially very useful approach to prioritizing which regimens should be tested in very long and expensive phase III trials," Rubin noted. "The use of phase II trials with a design similar to that of the current trial might get some of these new agents into later-phase clinical trials more rapidly."
Despite the encouraging results, it's not clear whether they will lead to improved TB outcomes, he added. "Although almost all drug combinations can kill the bulk of bacteria, a small subpopulation seems to be responsible for the lengthy regimens that are necessary to cure all patients," Rubin wrote. The trial's time-to-positivity results "most likely tell us more about the bulk population than about the rarer bacteria that might survive for extended times."
While the current trial "provides useful guidelines for prioritizing late-phase trials," those later trials will still be critical, he pointed out. Referencing the movie "The Princess Bride," Rubin reminded investigators and clinicians alike that, "as Miracle Max says, 'You rush a miracle man, you get rotten miracles.'"
The PARADIGM-4TB adaptive platform trial assigned participants with rifampin-susceptible pulmonary TB to receive standard HRZE for 24 weeks; bedaquiline, delamanid, and moxifloxacin for 16 weeks; or one of 10 new four-drug combinations for 16 weeks. The new regimens contained ganfeborole, BTZ-043, or both, with combinations of bedaquiline, delamanid, moxifloxacin, pyrazinamide, pretomanid, and linezolid.
Ganfeborole blocks an enzyme essential to mycobacterial protein synthesis, while BTZ-043 inhibits an essential enzyme in cell-wall synthesis.
The study enrolled 401 adults at 14 clinical sites in South Africa, Tanzania, Uganda, Vietnam, and Moldova. Patients had TB symptoms or chest radiography evidence, as well as a medium or high semiquantitative result on the Xpert MTB/RIF Ultra assay. Patients with HIV were excluded. Median patient age was 30 years, 84% were male, 68% had a high bacterial load, and 77% had cavitation on a chest radiograph.
Severe adverse events occurred in 38% of the BPMG group, 28% of the BDMT group, and 24% of the HRZE group. Among the trial's 118 patients who had a serious adverse event, 45% had a decrease from baseline in creatinine clearance, "which contributed to excess severe adverse events in some new-regimen groups," Paton and team noted. Most of those patients had creatinine clearance fall by more than 30%.
Study limitations included the open-label design and the small sizes of each treatment group. Time to positivity is a surrogate endpoint that hasn't always predicted clinical endpoints, the authors cautioned. While the study population included only those with rifampin-susceptible TB, any treatments' target clinical population would include patients with rifampin-resistant TB.
来源:MedPage Today · medpagetoday.com